within Pharmacolibrary.Drugs.ATC.A;

model A02BA06
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.5,
    Cl             = 0.00011166666666666667,
    adminDuration  = 600,
    adminMass      = 75 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.0012,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0031666666666666666,
    Tlag           = 10.200000000000001
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>A02BA06</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Roxatidine acetate is an H2-receptor antagonist used in the management of peptic ulcer disease and gastroesophageal reflux disease (GERD). It inhibits gastric acid secretion. While used in several countries, it is not approved for use in the United States or most EU countries.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters in healthy adult volunteers after oral administration.</p><h4>References</h4><ol><li><p>Li, X, et al., &amp; Tu, S (2022). Pharmacokinetics and Bioequivalence Studies of Roxatidine Acetate Hydrochloride Sustained-Release Capsule in Healthy Chinese Subjects. <i>Clinical pharmacology in drug development</i> 11(5) 597–605. DOI:<a href=&quot;https://doi.org/10.1002/cpdd.1053&quot;>10.1002/cpdd.1053</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/34978388/&quot;>https://pubmed.ncbi.nlm.nih.gov/34978388</a></p></li><li><p>Collins, JD, &amp; Pidgen, AW (1988). Pharmacokinetics of roxatidine in healthy volunteers. <i>Drugs</i> 35 Suppl 3 41–47. DOI:<a href=&quot;https://doi.org/10.2165/00003495-198800353-00009&quot;>10.2165/00003495-198800353-00009</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/2905248/&quot;>https://pubmed.ncbi.nlm.nih.gov/2905248</a></p></li><li><p>Nakamura, H, et al., &amp; Miyazawa, K (2012). Pharmacokinetics of the H(2) blocker roxatidine acetate hydrochloride in pediatric patients, in comparison with healthy adult volunteers. <i>Drug metabolism and pharmacokinetics</i> 27(4) 422–429. DOI:<a href=&quot;https://doi.org/10.2133/dmpk.dmpk-11-rg-112&quot;>10.2133/dmpk.dmpk-11-rg-112</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/22293541/&quot;>https://pubmed.ncbi.nlm.nih.gov/22293541</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end A02BA06;
